When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
A weekend leverage flush pushed BTC below $88,000 before a sharp rebound. Bitcoin is trading at a pivotal level that analysts say could determine whether the market holds its broader uptrend or slips ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...
Hi, I was trying to write a specification for an iterative fibonnaci sequence and decided to try the recursive definition for the method postcondition: public class Fibonacci { //@ requires n < 0; //@ ...
Is the S&P 500 index’s recent rally real, or is it just a bear-market bounce? That’s always a question investors have when the market is rising after a significant selloff. Given all the uncertainty ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results